Literature DB >> 22875707

Conditional survival of high-grade glioma in Los Angeles County during the year 1990-2000.

Denice D Tsao-Wei1, Jia Hu, Susan G Groshen, Marc C Chamberlain.   

Abstract

Survival probabilities for high-grade glioma are estimated at the time of diagnosis and provide limited information following treatment. This study determined dynamic indices to predict post-diagnosis survival for high-grade glioma patients. Survival information for 2,743 patients with high-grade glioma, diagnosed in Los Angeles County during the years 1990-2000, were used to estimate conditional survival probabilities with 95 % confidence intervals, for patients still alive at 1, 2, 3, 4, or 5 years after diagnosis. The conditional probabilities of surviving one additional year increase as the post-diagnosis survival time increases (from 43 ± 2 % conditional on surviving 1 year after diagnosis to 91 ± 2 % conditional on surviving 5 years after diagnosis). Patients diagnosed with WHO grade III gliomas have higher conditional survival probabilities than those diagnosed WHO grade IV gliomas. However, as the years after diagnosis increase, the differences in the conditional probabilities between the two groups are attenuated. At the time of diagnosis, age and tumor histology (WHO grade), tumor site, primary treatment, time of treatment start after diagnosis, as well as whether the patient was treated at a teaching hospital were significantly associated with overall survival. By 4 years post-diagnosis however, with the exception of age, variables associated with survival at baseline were no longer significantly associated with survival. Conditional survival probabilities provide clinically relevant information for understanding the prognosis for patients with high-grade gliomas.

Entities:  

Mesh:

Year:  2012        PMID: 22875707     DOI: 10.1007/s11060-012-0949-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  17 in total

1.  A comparison of two simple hazard ratio estimators based on the logrank test.

Authors:  G Berry; R M Kitchin; P A Mock
Journal:  Stat Med       Date:  1991-05       Impact factor: 2.373

Review 2.  Prognostic value of complete response after the initial treatment for malignant astrocytoma.

Authors:  T Kayama; T Kumabe; T Tominaga; T Yoshimoto
Journal:  Neurol Res       Date:  1996-08       Impact factor: 2.448

3.  Survival analysis for adult glioma in England and Wales.

Authors:  Min-Yuan Tseng; Jen-Ho Tseng
Journal:  J Formos Med Assoc       Date:  2005-05       Impact factor: 3.282

4.  Conditional probability of survival in patients with newly diagnosed glioblastoma.

Authors:  Mei-Yin C Polley; Kathleen R Lamborn; Susan M Chang; Nicholas Butowski; Jennifer L Clarke; Michael Prados
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation.

Authors:  J A Kraus; M Wenghoefer; M C Schmidt; A von Deimling; U Berweiler; W Roggendorf; S Diete; K Dietzmann; B Müller; K Heuser; G Reifenberger; U Schlegel
Journal:  J Neurol       Date:  2000-06       Impact factor: 4.849

Review 6.  Treatment options for glioblastoma.

Authors:  Marc C Chamberlain
Journal:  Neurosurg Focus       Date:  2006-04-15       Impact factor: 4.047

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

8.  Overall survival in patients with malignant glioma may be significantly longer with tumors located in deep grey matter.

Authors:  Ramachandran Ramnarayan; Susanna Dodd; Kumar Das; Volkmar Heidecke; Nikolai G Rainov
Journal:  J Neurol Sci       Date:  2007-05-01       Impact factor: 3.181

9.  The conditional probabilities of survival in patients with anaplastic astrocytoma or glioblastoma multiforme.

Authors:  C L Lin; A S Lieu; K S Lee; Y H C Yang; T H Kuo; M H Hung; J K Loh; C P Yen; C Z Chang; S L Howng; S L Hwang
Journal:  Surg Neurol       Date:  2003-11

Review 10.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

View more
  7 in total

1.  Prognostic value of age in neurological cancer: an analysis of 22,393 cases from the SEER database.

Authors:  Minjie Tian; Donglin Zhu; Daowen Chen; Xiaoli Huo; Jianqing Ge; Jie Lu; Li Zhang; Jingping Shi
Journal:  Tumour Biol       Date:  2015-05-27

2.  Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma.

Authors:  Houyi Kang; Peng Chen; Hong Guo; Letian Zhang; Yong Tan; Hualiang Xiao; Ao Yang; Jingqin Fang; Weiguo Zhang
Journal:  Cancer Manag Res       Date:  2020-10-08       Impact factor: 3.989

3.  Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.

Authors:  Maria Teresa Solomon; Nederlay Miranda; Eugenia Jorrín; Ivonne Chon; Jorge Juan Marinello; José Alert; Patricia Lorenzo-Luaces; Tania Crombet
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

4.  Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Caroline Chung; Barbara-Ann Millar; Arjun Sahgal; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-29       Impact factor: 4.130

5.  Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012.

Authors:  Paul Farah; Rachel Blanda; Courtney Kromer; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2016-04-19       Impact factor: 4.130

6.  MicroRNA-650 expression in glioma is associated with prognosis of patients.

Authors:  Boqian Sun; Bo Pu; Dake Chu; Xiaodan Chu; Wei Li; Dun Wei
Journal:  J Neurooncol       Date:  2013-09-24       Impact factor: 4.130

7.  Long Term Survivals in Aggressive Primary Brain Malignancies Treated With an Adjuvant Ketogenic Diet.

Authors:  Kenneth A Schwartz; Mary Noel; Michele Nikolai; Lawrence K Olson; Norman G Hord; Micheal Zakem; Justin Clark; Mohamed Elnabtity; Bryan Figueroa; Howard T Chang
Journal:  Front Nutr       Date:  2022-05-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.